GlassScriptPhysician profile
Vibha Jain
NPI 1669676060
$209,416.98
in general payments reported to CMS, 2019-2025
12 companies · $42K in 2025
The $42K reported for 2025 was more than what 98% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
See the full distribution for Anatomic Pathology & Clinical Pathology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $88.92 · 2021: $20K · 2022: $41K · 2023: $52K · 2024: $53K · 2025: $42K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $148K · Food and Beverage: $230 · Education: $19.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $147,675.00 |
| Food and Beverage | $230.26 |
| Education | $19.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Plasma INC. | $147,675.00 | 2023-2025 | |
| Csl Behring | $60,855.00 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $217.57 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2024 | |
| Alexion Pharmaceuticals, INC. | $125.00 | 2019 | |
| Urogen Pharma, INC. | $119.72 | 2022 | |
| Medtronic, INC. | $82.20 | 2024 | Azure Xt Dr Mri Surescan |
| E.R. Squibb & Sons, L.L.C. | $69.48 | 2022 | |
| Stemline Therapeutics INC. | $65.10 | 2020 | |
| Alnylam Pharmaceuticals INC. | $42.54 | 2023 | Givlaari, Oxlumo |
| Endo Pharmaceuticals INC. | $23.82 | 2020 | |
| Urovant Sciences INC | $16.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vibha Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.